INT19620

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1990
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 30
Total Number 32
Disease Relevance 12.01
Pain Relevance 9.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD86) cell-cell signaling (CD86)
Anatomy Link Frequency
CD86 16
T-cell 9
ECs 2
Plasma 1
hinge 1
CD86 (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 821 99.98 Very High Very High Very High
local anesthetic 4 99.80 Very High Very High Very High
Inflammation 155 98.88 Very High Very High Very High
rheumatoid arthritis 374 97.88 Very High Very High Very High
psoriasis 14 96.00 Very High Very High Very High
antagonist 14 93.76 High High
cytokine 93 89.20 High High
Arthritis 232 86.24 High High
Pain 29 83.92 Quite High
tolerance 30 80.64 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 171 98.88 Very High Very High Very High
Adhesions 24 98.18 Very High Very High Very High
Rheumatoid Arthritis 379 97.88 Very High Very High Very High
Psoriasis 14 96.00 Very High Very High Very High
Autoimmune Disease 39 95.12 Very High Very High Very High
Hookworm Infection 70 93.32 High High
Necrosis 28 93.00 High High
Cancer 76 92.64 High High
Apoptosis 7 91.52 High High
Disease 233 91.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
One of the best-characterized costimulatory pathways is the engagement of CD 80/CD86 on antigen-presenting cells (APCs) with CD 28 on T-cells (Figure 1a).
CD86 Binding (engagement) of in T-cells
1) Confidence 0.47 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727897 Disease Relevance 0.29 Pain Relevance 0.23
The fusion protein abatacept is a selective costimulation modulator that avidly binds to the CD80/CD86 ligands on an antigen-presenting cell, resulting in the inability of these ligands to engage the CD28 receptor on the T cell.
CD86 Binding (binds) of in CD86 associated with abatacept
2) Confidence 0.47 Published 2005 Journal J Clin Rheumatol Section Abstract Doc Link 16357751 Disease Relevance 0.59 Pain Relevance 0.52
Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation.
CD86 Binding (binding) of in T-cell associated with abatacept
3) Confidence 0.47 Published 2007 Journal Adv Ther Section Abstract Doc Link 17565924 Disease Relevance 0.73 Pain Relevance 0.71
Abatacept, a selective co-stimulation modulator, inhibits CD28-dependent T-cell activation by binding to CD80 and CD86 [4].
CD86 Binding (binding) of in CD86 associated with abatacept
4) Confidence 0.45 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.28 Pain Relevance 0.79
Identical results were obtained for T cell adhesion using either CTLA-4 blocking mAb or CTLA-4Ig (abatacept), indicating CTLA-4 as the T cell ligand for these CD86-mediated effects.
CD86 Binding (ligand) of in T cell associated with abatacept and adhesions
5) Confidence 0.36 Published 2008 Journal J. Immunol. Section Abstract Doc Link 18941200 Disease Relevance 0.51 Pain Relevance 0.15
Freshly isolated human islet ECs constitutively expressed CD86 (B7-2) and ICOS ligand but not CD80 (B7-1) or CD40 costimulatory molecules.
CD86 Binding (ligand) of in ECs
6) Confidence 0.36 Published 2008 Journal J. Immunol. Section Abstract Doc Link 18941200 Disease Relevance 0.46 Pain Relevance 0.09
The most important ligand is CTLA-4, a well-defined down-regulator of T-cell activation, which has a much higher binding affinity for CD80/CD86 than CD28.
CD86 Binding (binding) of in T-cell
7) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727897 Disease Relevance 0.30 Pain Relevance 0.64
Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway.
CD86 Binding (binds) of in T cells associated with inflammation, rheumatoid arthritis and abatacept
8) Confidence 0.36 Published 2009 Journal Ugeskr. Laeg. Section Abstract Doc Link 19174034 Disease Relevance 0.26 Pain Relevance 0.40
Freshly isolated human islet ECs constitutively expressed CD86 (B7-2) and ICOS ligand but not CD80 (B7-1) or CD40 costimulatory molecules.
B7-2 Binding (ligand) of in ECs
9) Confidence 0.36 Published 2008 Journal J. Immunol. Section Abstract Doc Link 18941200 Disease Relevance 0.46 Pain Relevance 0.09
The second, or co-stimulatory, signal is delivered following the engagement of CD80/CD86 on antigen-presenting cells with a cognate receptor, CD28, on the surface of the T cell [6,7].
CD86 Binding (engagement) of in T cell
10) Confidence 0.35 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.29 Pain Relevance 0.69
An example is abatacept (soluble cytotoxic-T-lymphocyte-associated protein 4-immunoglobulin), which binds with high affinity to CD80/CD86 and effectively suppresses inflammatory activity in RA.
CD86 Binding (binds) of in T-lymphocyte associated with inflammation, rheumatoid arthritis and abatacept
11) Confidence 0.35 Published 2006 Journal Nature clinical practice. Rheumatology Section Abstract Doc Link 16932686 Disease Relevance 0.83 Pain Relevance 0.40
The new biological agent abatacept, a recombinant protein consisting of the extracellular region of the human cytotoxic T-lymphocyte-associated antigen (CTLA)-4 receptor fused to the constant fragment (Fc) region of IgG1, binds to the CD80/CD86 molecules on antigen-presenting cells and modulates T-cell activation.
CD86 Binding (binds) of in T-cell associated with abatacept
12) Confidence 0.35 Published 2009 Journal Clin Drug Investig Section Abstract Doc Link 19243211 Disease Relevance 0.85 Pain Relevance 0.82
CTLA-4 binds to CD80 and CD86 with higher avidity than CD28, thus preventing co-stimulation through this pathway, and is a major down-regulatory signal for T cells.
CD86 Binding (binds) of in CD86
13) Confidence 0.35 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2569144 Disease Relevance 0.52 Pain Relevance 0.51
BACKGROUND: It has been proposed that ligation of CD80 and CD86 induces reverse signaling into antigen-presenting cells.
CD86 Binding (ligation) of in CD86
14) Confidence 0.34 Published 2009 Journal J. Clin. Immunol. Section Abstract Doc Link 19259798 Disease Relevance 0 Pain Relevance 0.17
Furthermore, no gene changes were observed in response to belatacept, a modified version of abatacept that binds with higher avidity to CD80 and CD86.
CD86 Binding (binds) of in CD86
15) Confidence 0.34 Published 2009 Journal J. Clin. Immunol. Section Body Doc Link 19259798 Disease Relevance 0 Pain Relevance 0
Its binding avidity to CD80 and CD86 was twofold and fourfold higher, respectively, and inhibition of T-cell activation was tenfold more powerful than those of CTLA4-Ig.
CD86 Binding (binding) of in CD86
16) Confidence 0.29 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721321 Disease Relevance 0.17 Pain Relevance 0.14
By binding to CD80 and CD86 ligands on the APCs it prevents a costimulatory signal by CD28 (Dumont 2004).
CD86 Binding (binding) of in CD86
17) Confidence 0.27 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.32 Pain Relevance 0.38
It competes with CD28 for binding to CD80/CD86 with a much higher affinity for these ligands, and provides a negative feedback loop (Sfikakis & Via 1997).
CD86 Binding (binding) of in CD86
18) Confidence 0.27 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.31 Pain Relevance 0.30
Using a rational mutagenesis and screening strategy, a daughter molecule, LEA29Y (belatacept, Bristol-Myers Squibb, New York, NY, USA), with two amino acid substitutions (L104->E and A29->Y), was developed.26 Belatacept was found to bind four times more avidly to CD86 and two times more avidly to CD80 than the parent compound, abatacept.
CD86 Binding (bind) of in CD86 associated with abatacept
19) Confidence 0.27 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.30 Pain Relevance 0.35
Thus, in abatacept, a series of directed cysteine to serine mutations were introduced in the hinge region to reduce this Fc- mediated binding.21 Although abatacept proved to be highly efficacious for autoimmune T cell-mediated autoimmune disorders, such as rheumatoid arthritis and psoriasis, it was found to be an inadequate maintenance immunosuppressive agent in nonhuman primate models of transplantation.22–24 Studies into potential reasons for this disconnect found that although CTLA4 binds with a much higher avidity to CD80 and CD86 than does CD28, CTLA4-Ig was significantly less potent at inhibiting CD86-dependent as opposed to CD80-dependent costimulation.25
CD86 Binding (binds) of in hinge associated with psoriasis, autoimmune disease, rheumatoid arthritis and abatacept
20) Confidence 0.27 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.29 Pain Relevance 0.39

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox